teva Rise Challenge

Shaping the future of healthcare with Teva

Your bridge from innovation to global impact

At Teva Rise, We Believe Real Impact Happens Together.

By combining your disruptive ideas with our global scale, expertise and access, we can turn innovation into solutions that improve lives and **shape the future of the healthcare.**

teva Rise Challenge

www.tevarise.com

Teva - The Ultimate Pharma Tech Launchpad Built for Scale

A global pharma leader

53
sites in 60 markets

37,000
industry experts

More than
200M
patients served daily

What makes Teva unique

- Full end-to-end pharma value chain
  R&D → Clinical → Manufacturing → Supply chain → Commercial
- Active across the full pharma spectrum
  Innovative medicines, generics, OTC, medical devices, hospital products and more

teva Rise Challenge

www.tevarise.com

Partner With Teva - From Pilot to Proof to Global Scale and Redefining The Healthcare Together

We offer startups more than collaboration - we offer acceleration

- Fully funded pilots no equity
- Direct access to decision-makers and domain experts
- Defined path to commercial deployment
- Fast track to proof and global scale
- Global visibility and market reach across 60 countries



teva Rise Challenge

www.tevarise.com

Come Rise With Us

Our Fast Track Bridge to Teva

Teva Rise matches Teva's high-value business and operational challenges with startups ready to pilot and scale.

Teva Rise focuses on innovation that drives measurable outcomes across:

- R&D and Digital Health
- Manufacturing and Automation
- Supply Chain and Sustainability
- Commercial and Data Analytics
- Patient & Consumer Experience

teva Rise Challenge

www.tevarise.com

Real challenges. Real impact

Our First Cohort of Challenges

Commercial & Medical Affairs

- Revolutionizing Patient Experience of Long-Acting Injectables
- Tender Value Optimization

Operations & Supply Chain

- Asset Reliability & Predictive Maintenance
- Product Quality & Risk Prediction
- Resource Allocation Intelligence

R&D

- AI-Powered Protocol Design for Clinical Trial Simulations
- Human-Predictive Platforms for Testing of Biologics, as An Alternative to Animal Models

Ready to Rise?

Your path from idea to impact

Accepting Applications
Until January 16th

Screening & Evaluation
January - February

Finalist Pitches
March

Winners Announced
April

Pilots Design & Launch
May

teva Rise Challenge

www.tevarise.com

Challenge no. 1RD

Human-Predictive Platforms for Testing of Biologics, as an alternative to Animal Models

Business Unit:

Research & Development

Challenge Description

How can we utilize human-based systems, as an alternative to animal models, for evaluating biologics' efficacy and safety in preclinical drug development, while accounting for human heterogeneity and immune system microenvironments?

Background & Current State

Recent regulatory changes, such as the FDA Modernization Act 2.0 and the FDA's 2025 roadmap, are accelerating the shift away from animal testing in drug development, especially for biologics. Traditional animal models are increasingly seen as limited in their ability to predict human responses, and new approach methodologies (NAMs) - including organoids, organ-on-a-chip systems, and AI-driven simulations - offer the potential for more relevant, efficient, and ethical preclinical testing. However, these human-based models must be scientifically validated, reproducible, and scalable for high-throughput screening, and their integration into existing pipelines remains a significant challenge.

Desired Outcome

Validated, scalable human-predictive platforms that can partially or fully replace animal models in biologics testing, accelerating drug development and improving human relevance.

Required impact:

- Increased use of human-relevant models in preclinical testing
- Faster and more predictive insights into drug safety and efficacy
- Reduced reliance on animal studies and associated costs
- Improved regulatory acceptance and alignment with evolving guidelines

What We're Looking For

We are seeking validated, scalable solutions that can generate human-based, high-throughput systems for evaluating the efficacy and safety of biological drugs, accounting for human heterogeneity and immune system complexity.

Functional Requirements

- → Accurately model human biological responses, including immune system and tissue microenvironment
- → Enable high-throughput screening and parallel testing of multiple candidates
- → Demonstrate scientific validation, reproducibility, and regulatory readiness
- → Adaptable to different biologic modalities and disease areas

Technical Requirements

- → Scientifically validated and reproducible.
- → Scalable and cost-effective for broad adoption
- → Gradually Integrate with existing R&D and preclinical workflows

General Requirements

- → Corporate-ready team & product
- → Validated technologies with proven market adoption
- → Compliant with regulatory standards and ethical guidelines

Sample Solutions

Solutions may include, but are not limited to:

- → Organoids: miniaturized, lab-grown 3D structures that mimic human organs.
- → Organ-on-a-Chip platforms: microfluidic devices simulating organ-level functions using human cells.
- → AI-based in silico human models: computational simulations using human biological data to predict drug behavior.
- → Hybrid platforms combining human cell-based assays with AI for predictive modeling

teva Rise Challenge

Submit your solution at www.tevarise.com or contact us at info@tevarise.com

Challenge no. 2RD

AI-Powered Protocol Design for Clinical Trial Simulations

Business Unit:
Research & Development

Challenge Description

How can we utilize AI-powered simulation technologies to accelerate protocol design, optimize clinical study feasibility, and enable earlier data-driven decisions?

Background & Current State

Clinical trial protocol design is currently a manual, sequential process that relies heavily on expert judgment and historical precedent. Feasibility assessments are typically conducted after protocol drafting, often resulting in rework, amendments, and delays. There is limited integration of real-world data, predictive modeling, or scenario testing in early planning stages, which leads to inefficiencies, higher costs, and slower trial initiation. Protocol amendments are common and disruptive, representing the largest cause of unplanned delays and unbudgeted costs in clinical trials.

Desired Outcome

A data-driven, AI-enabled protocol design process that reduces amendments, accelerates trial initiation, and improves patient recruitment and retention.

Required impact:

- Faster protocol design and feasibility evaluation
- Fewer protocol amendments and reduced associated costs
- Improved patient targeting, recruitment, and retention
- Enhanced cross-functional team alignment and decision-making
- Reduced operational “white space” and time to market

What We’re Looking For

We are seeking innovative, scalable solutions - such as AI-powered simulation platforms or advanced analytics tools - that can transform protocol design and feasibility assessment.

Functional Requirements

- → Simulate multiple protocol scenarios in real time, integrating historical data, feasibility metrics, and operational constraints
- → Support scenario analysis and predictive modeling to guide optimal protocol design
- → Enable cross-functional collaboration and alignment through shared simulations and data-driven insights
- → Reduce manual workload and streamline protocol development workflows

Technical Requirements

- → Integrate with existing clinical development and data management systems
- → Scalable across multiple studies and therapeutic areas

General Requirements

- → Corporate-ready team & product
- → Validated technologies with proven market adoption
- → Solutions must comply with Teva’s internal IT security, data privacy, and regulatory requirements
- → User-friendly interface for clinical development teams
- → Adaptable to evolving clinical trial requirements

Sample Solutions

Solutions may include, but are not limited to:

- → AI-powered clinical trial simulation platforms
- → Predictive analytics for protocol feasibility and patient recruitment
- → Scenario modeling and optimization tools for clinical development
- → Digital collaboration and workflow solutions for protocol design

teva Rise Challenge

Submit your solution at www.tevarise.com or contact us at info@tevarise.com

Challenge no. 3C

Revolutionizing Patient Experience of Long-Acting Injectables

Business Unit:
Medical Affairs
Support by Commercial

Challenge Description

How can we improve patient experience, remove usage barriers, and increase treatment continuation of monthly LAI antipsychotics compared to daily oral treatments?

Background & Current State

Long-acting injectables (LAIs) for schizophrenia hold multiple benefits for patients yet adoption in Europe remains below 30%. Daily orals are still preferred due to lower cost, familiarity, and perceived patient resistance to injections. Previous efforts—such as educational campaigns and pilot clinics—have had limited impact, as they often fail to address emotional, behavioral, and systemic barriers for patients, physicians, and caregivers. As a result, suboptimal adherence persists, leading to higher relapse rates, increased healthcare costs, and missed opportunities for improved patient outcomes.

Desired Outcome

A measurable increase in LAI adoption, resulting in improved patient outcomes and reduced healthcare costs.

Required impact:

- Higher rates of LAI initiation
- Improved treatment continuation and reduced relapse/hospitalization rates
- Increased physician confidence and willingness to prescribe LAIs
- Reduced caregiver burden and improved quality of life
- Easy Integration of LAIs into clinical workflows and health systems

What We're Looking For

We are seeking a wide range of patient-centric solutions - across digital, behavioral, educational, and system-level interventions - that can be integrated into different stages of the patient journey, and positively support patient perception, continuation, and education regarding long-acting injectables (LAIs) for schizophrenia. Solutions may address any combination of the following:

- → Supporting physicians in engaging patients and addressing barriers to LAI adoption
- → Shifting patient and caregiver perceptions to reduce fear, stigma, or misconceptions about LAIs
- → Enhancing patient education and understanding of the benefits and process of LAI treatment
- → Improving the overall experience of LAI initiation and ongoing use
- → Leveraging technology, community, or novel service models to increase acceptance and sustained use of LAIs

We welcome creative, scalable patient-centric approaches that address different stages of the patient journey, and can be piloted and adapted to different healthcare settings, with the potential for measurable impact on LAI adoption and continuation.

Sample Solutions

Solutions may include, but are not limited to:

- → Behavioral change interventions and support tools
- → Technology-enabled adherence monitoring
- → Needle-free or pain-reducing injection technologies
- → Workflow optimization solutions for clinics & caregivers
- → Digital patient engagement and education platforms

teva Rise Challenge

Submit your solution at www.tevarise.com or contact us at info@tevarise.com

Challenge no. 4C

Tender Value Optimization

Business Unit:
Commercial

Challenge Description

How can we leverage advanced analytics, modeling, and decision-support systems to enhance tender success and profitability, outperforming historical results.

Background & Current State

Optimizing tender pricing is critical for maximizing profitability and market share across pharmaceutical products, but current approaches are fragmented, labor-intensive, and rely heavily on historical performance and manual analysis. The diversity of tender formats, evaluation criteria, and competitive dynamics makes it difficult to systematically optimize outcomes, often resulting in missed opportunities and suboptimal pricing decisions. There is no integrated solution that brings together all relevant data sources and parameters to support data-driven, strategic tender participation in a standardized process across different markets in the EU Region.

Desired Outcome

A data-driven, system-enabled approach to tender optimization that improves profitability and competitive performance across different markets and tender formats.

Required impact:

- Higher tender win rates and profitability per tender
- Increased overall market share and ROI on tender participation
- Integrated utilization of multiple data sources for decision-making
- Improved performance versus competitors and historical benchmarks

What We're Looking For

We are seeking innovative, scalable solutions - such as advanced analytics platforms, optimization models, or decision-support tools - that can systematically improve tender pricing and participation outcomes.

Functional Requirements

- → Integrate historical tender data, competitor performance, market dynamics, and internal constraints
- → Support scenario analysis and predictive modeling for pricing decisions
- → Focus on commonalities across tender variations to maximize applicability
- → Incorporate best practices in pharma tendering, including game theory and unique value offerings

Technical Requirements

- → Integration with existing commercial, pricing, and market access systems.
- → Auditability and traceability of data flows and predictions.
- → Support for role-based access control (RBAC)

General Requirements

- → Corporate-ready team & product
- → Validated technologies with proven market adoption
- → Solutions must comply with Teva's internal IT security, data privacy, and regulatory requirements
- → User-friendly interface for commercial and pricing teams
- → Scalable and adaptable to different tender formats and geographies

Sample Solutions

Solutions may include, but are not limited to:

- → Advanced tender analytics and optimization platforms
- → AI/ML-based pricing and scenario simulation tools
- → Decision-support systems for tender participation
- → Game theory-based tender strategy modules
- → Market intelligence and competitor benchmarking solutions

teva Rise Challenge

Submit your solution at www.tevarise.com or contact us at info@tevarise.com

Challenge no. 5TS

Asset Reliability & Predictive Maintenance

Business Unit:
Global Operations & Supply Chain

Challenge Description

How can we predict and prevent unexpected equipment failures across critical manufacturing assets using available historical and real-time data with modular, system-compatible solutions?

Background & Current State

Unexpected equipment failures at manufacturing sites threaten safety, supply performance, and patient access, as current maintenance is mostly reactive and relies on historical data without predictive analytics. While a large volume of maintenance data exists in SAP PM and Ariba, it is difficult to analyze and use proactively, and maintenance practices lack global standardization - resulting in inefficiencies, higher costs, and challenges in forecasting service and spare part needs.

Desired Outcome

A proactive, predictive maintenance approach that integrates historical and real-time data to improve reliability and efficiency across prioritized assets and sites.

Required improvements:

- Increased reliability of critical assets
- Reduction in unplanned downtime and reactive maintenance
- Lower maintenance costs and optimized resource allocation
- Improved manufacturing plan adherence and line output
- Engineering time redirected to value-added initiatives

What We're Looking For

Solutions should focus on critical assets and high-spend sites, functioning as plug-ins or operating alongside existing systems, leveraging historical asset data, performance metrics, and real-time monitoring where available.

Functional Requirements

- → Predict & prevent failures using integrated historical and real-time data
- → Provide actionable maintenance recommendations and enable cost forecasting
- → Standardized & broadly applicable across diverse asset types
- → Focus on analytics, integration, and predictive insights (data provision and quality are Teva's responsibility)

Technical Requirements

- → Modular and compatible with existing SAP PM.
- → Scalable across multiple sites and asset types
- → Auditability and traceability of data flows and predictions.
- → Support for role-based access control (RBAC)
- → Cloud architecture is preferred.

General Requirements

- → Corporate-ready team & product
- → Validated technologies with proven market adoption
- → Solutions must comply with Teva's internal IT security, data privacy, and regulatory requirements
- → Should complement, not replace, existing maintenance systems

Sample Solutions

Include, but are not limited to:

- → Asset performance management (APM) solutions
- → Predictive maintenance platforms
- → AI/ML-based failure prediction tools
- → Data integration and visualization tools
- → IoT-enabled real-time monitoring systems
- → Maintenance cost forecasting and optimization tools

teva Rise Challenge

Submit your solution at www.tevarise.com or contact us at info@tevarise.com

Challenge no. 6TS

Product Quality & Risk Prediction

Business Unit:

Global Operations & Supply Chain

Challenge Description

How can we consolidate diverse data sources to predict and quantify product quality risks, and deliver actionable insights for proactive risk mitigation and supply continuity?

Background & Current State

Assessing and predicting product quality is challenging due to unquantified variability in raw materials, manufacturing processes, and quality control testing - which are not consolidated for analysis. Product robustness, (a product's ability to consistently meet quality standards despite variability in materials and processes), is not systematically measured. Current methods, including Continuous Process Verification (CPV), rely on annual, retrospective reviews of historical data and do not provide real-time or predictive insights. As a result, quality risks are often detected too late for effective intervention, leading to reactive risk mitigation and missed opportunities to prevent failures, supply disruptions, or costly write-offs.

Desired Outcome

A predictive, actionable assessment of product robustness that highlights process risks and guides mitigation efforts

Required improvements:

- Consolidated assessment of product robustness across multiple process and quality data sources
- Identification of high-risk products and actionable mitigation guidance
- Reduced quality failures, write-offs, deviations, and supply disruptions
- Improved Right First Time (RFT) performance and overall manufacturing efficiency
- Automated, data-driven visibility into manufacturing and quality risks

What We're Looking For

We are seeking scalable, data-driven solutions that can integrate and analyze diverse sources of manufacturing and quality data to proactively assess and predict product robustness and quality risks.

Functional Requirements

- Consolidate and analyze data from multiple sources (materials, processes, QC, stability)
- Quantify product robustness and predict quality risks
- Provide actionable guidance for risk mitigation
- Focus on analytics, integration, and predictive insights (data provision and quality are Teva's responsibility)

Technical Requirements

- Integration & compatibility with Azure Data hub, supporting Azure authentication mechanisms.
- Ability to provide APIs or connectors compatible with Databricks.
- Auditability and traceability of data flows and predictions.
- Support for role-based access control (RBAC)

General Requirements

- Corporate-ready team & product
- Validated technologies with proven market adoption
- Solutions must comply with Teva's internal IT security, data privacy, and regulatory requirements
- Generic and standardized across multiple products and processes

Sample Solutions

Solutions include, but are not limited to:

- AI/ML-based product robustness assessment tools
- Data integration and visualization solutions for manufacturing and quality
- Predictive quality analytics platforms
- Automated risk scoring and alerting systems
- Digital twins for process and quality risk simulation

teva Rise Challenge

Submit your solution at www.tevarise.com or contact us at info@tevarise.com

Challenge no. 7TS

Resource Allocation Intelligence

Business Unit:
Global Operations & Supply Chain

Challenge Description

How can we optimize the allocation of limited resources during shortages through an integrated, scenario-based decision framework that quantifies trade-offs, maximizes profitability, and reduces lost sales?

Background & Current State

Pharma players frequently face shortages of key resources - such as materials, finished products, and equipment - which can prevent the company from meeting commercial opportunities or fulfilling existing supply commitments. Currently, allocation decisions are made manually, with teams gathering data from multiple sources and using spreadsheets and presentations to recommend how to split limited resources. This process is time-consuming, reactive, and often based on incomplete or inaccurate data, as customers may inflate forecasts to secure a larger share. There is no integrated system to support scenario analysis or quantify the risks and trade-offs of different allocation decisions, resulting in suboptimal outcomes and lost sales.

Desired Outcome

A streamlined, data-driven allocation process that enables proactive, optimal decision-making and reduces lost sales and manual workload.

Required improvements:

- Improved realization of compelling market opportunities
- Reduction in lost sales due to allocation constraints
- Reduction in headcount and manual effort dedicated to the allocation process
- Improved visibility into allocation impacts and trade-offs
- Enhanced ability to simulate scenarios and future constraints

What We're Looking For

We are seeking modular, intelligent solutions that integrate with Teva's existing systems to automate data extraction, enable scenario analysis, and recommend optimal allocation strategies.

Functional Requirements

- → Automatically extract and consolidate relevant resource and demand data from Teva's systems
- → Enable scenario simulation and "what if" analysis for allocation constraints
- → Recommend allocations to optimize profitability and minimize lost sales, considering demand variability and penalties
- → Present insights with supporting data and allow user overrides with visibility into expected impacts
- → Write back final decisions to planning systems for execution

Technical Requirements

- → Integration with SAP S3/S4 Hana, SAP IBP, SAP MDG, and SAP Analytical Cloud
- → Support bidirectional data flow
- → Auditability and traceability of data flows and predictions.
- → Support for role-based access control (RBAC)

General Requirements

- → Corporate-ready team & product
- → Validated technologies with proven market adoption
- → Solutions must comply with Teva's internal IT security, data privacy, and regulatory requirements
- → Modular design that enhances, not replaces, existing ERP and planning tools
- → Scalable to support multiple allocation cases simultaneously

Sample Solutions

Solutions include, but are not limited to:

- → Advanced allocation and optimization engines
- → Scenario-based decision support platforms
- → AI/ML-driven demand and supply forecasting tools
- → Integrated business planning (IBP) enhancement modules
- → Data visualization and simulation tools for supply chain management

teva Rise Challenge

Submit your solution at www.tevarise.com or contact us at info@tevarise.com

teva Rise Challenge

The bridge where innovation meets reality.
Turning ideas into impact.

Come Rise with us

Submit your solution at:

www.tevarise.com

| For more information: info@tevarise.com